Clinical trials: Advanced Breast Cancer Stage IV
Locally Advanced Breast Cancer, Breast Cancer
Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca
Women with breast cancer undergo treatments that decrease the chance of recurrence of cancer, but are associated with several side effects, including declines in memory and attention and other thinking abilities.
- Trial name
- Cyto-Cog (NCT00756132)
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Breast Neoplasms
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.
- Trial name
- NCT00097721
- Testing
- E7389
- Where
- 16 sites in United States
- Volunteers
- 104 people
- Sponsor
- Eisai Inc.
Breast Cancer Metastatic
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
This study is a prospective, open-label, phase III clinical study for patients with HR+/HER2- advanced breast cancer.
- Trial name
- NCT06612814
- Testing
- Fluzoparib, Dalpiciclib, Fulvestrant/AI
- Where
- China
- Volunteers
- 307 people
- Sponsor
- Zhimin Shao
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer and Ovarian Cancer
Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer
This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.
- Trial name
- NCT03055143
- Testing
- SPARC-08-038, Ref-08-038
- Volunteers
- 29 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of BEBT-209 in combination with fulvestrant in patients with HR+/HER2- locally…
- Trial name
- NCT06998108
- Testing
- BEBT-209 capsules, Fulvestrant Injection
- Where
- China
- Volunteers
- 330 people
- Sponsor
- BeBetter Med Inc
Breast Cancer
Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer
Hormone therapy is the primary treatment option for patients with HR+ HER2- breast cancer. Despite its activity, hormone therapy is associated with initial, or more frequently acquired, resistance after exposure to one or more…
- Trial name
- PALBOSPAIN (NCT04874025)
- Testing
- Ibrance
- Where
- 36 sites in Spain
- Volunteers
- 815 people
- Sponsor
- Hospital San Carlos, Madrid
Metastatic Breast Cancer
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
This study adopted a randomized, open-label, positive drug-controlled, multi-center trial design. The primary endpoint was PFS evaluated by the Independent Review Committee (IRC).
- Trial name
- NCT07008976
- Testing
- TQB2102 Injection, Trastuzumab Emtansine for Injection
- Where
- 31 sites in China
- Volunteers
- 246 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery
RATIONALE: Comparing results of diagnostic procedures, such as molecular marker profiling, done before and after chemotherapy, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00233974
- Testing
- PET (positron emission tomography)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stage IV Breast Cancer, Recurrent Breast Cancer
Antineoplaston Therapy in Treating Women With Advanced Breast Cancer
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Trial name
- NCT00003455
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Advanced Breast Cancer
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
The goal of this clinical trial is to prove that the RECAP test is capable of selecting advanced breast cancer patients sensitive for treatment with the PARP inhibitor talazoparib.
- Trial name
- FUTURE (NCT06193525)
- Testing
- Talazoparib
- Where
- 3 sites in Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Breast Cancer Metastatic
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
- Trial name
- NCT06750484
- Testing
- Trastuzumab Deruxtecan
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Neoplasms, Breast
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
- Trial name
- NCT00338247
- Testing
- lapatinib + capecitabine
- Where
- 453 sites in United States, Australia and 43 more
- Sponsor
- Novartis
Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
This study evaluates the change of quality of life, treatment decision and utilization of health care depending on the use of palliative care in advanced cancer patients by a prospective cohort study.
- Conditions
- Stage IV Breast Cancer, Stage IV Pancreatic Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer
- Trial name
- NCT03222258
- Testing
- Early palliative care, Routine hospice care
- Where
- 15 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Seoul National University Hospital
Metastatic Breast Cancer
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
The purpose of this study is to determine whether IMC-A12 offers increased progression-free survival (PFS) associated with IMC-A12 monotherapy and IMC-A12 in combination with an antiestrogen therapy in patients with hormone…
- Trial name
- NCT00728949
- Testing
- IMC-A12 (cixutumumab), tamoxifen, Anastrozole
- Where
- 9 sites in United States
- Volunteers
- 93 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer, HER2-positive Breast Cancer
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of pyrotinib combination with CDK4/6 Inhibitor SHR6390 in advanced HER2-Positive breast cancer patients who prior trastuzumab-treated.
- Trial name
- INPHASE (NCT04095390)
- Testing
- Pyrotinib, SHR6390, Letrozole
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jinming Yu
Breast Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00030537
- Testing
- erlotinib hydrochloride
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Breast Cancer Metastatic
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers.
- Conditions
- Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- INX-315-01 (NCT05735080)
- Testing
- INX-315, Fulvestrant, Abemaciclib
- Where
- 18 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Incyclix Bio
HER2-negative Breast Cancer, Hormone Receptor Positive Tumor
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients…
- Conditions
- HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT07227831
- Testing
- TheraBionic P1
- Where
- 8 sites in United States
- Volunteers
- 82 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Breast Carcinoma, Advanced Colon Carcinoma
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have…
- Conditions
- Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma
- Trial name
- NCT04704661
- Testing
- Biopsy Procedure, Biospecimen Collection, Ceralasertib
- Where
- 23 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.